Kenvue Inc. $KVUE Shares Acquired by Moors & Cabot Inc.

Moors & Cabot Inc. increased its position in Kenvue Inc. (NYSE:KVUE) by 66.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 313,122 shares of the company’s stock after purchasing an additional 125,517 shares during the period. Moors & Cabot Inc.’s holdings in Kenvue were worth $5,082,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in KVUE. Norges Bank purchased a new stake in Kenvue in the second quarter valued at approximately $537,418,000. Independent Franchise Partners LLP grew its position in shares of Kenvue by 233.4% during the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after acquiring an additional 21,886,537 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Kenvue by 101.3% in the 3rd quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after acquiring an additional 9,240,434 shares during the period. American Century Companies Inc. increased its holdings in shares of Kenvue by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after acquiring an additional 8,436,166 shares during the period. Finally, Amundi raised its position in Kenvue by 82.5% in the 2nd quarter. Amundi now owns 14,509,890 shares of the company’s stock valued at $305,446,000 after purchasing an additional 6,559,261 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Up 1.3%

Shares of NYSE:KVUE opened at $17.72 on Tuesday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. The firm’s 50-day simple moving average is $17.91 and its 200-day simple moving average is $17.26. The company has a market cap of $33.95 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 3.97 and a beta of 0.51.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The firm had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. During the same period in the prior year, the company posted $0.26 earnings per share. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. The ex-dividend date was Wednesday, February 11th. Kenvue’s payout ratio is presently 107.79%.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Argus upgraded Kenvue to a “hold” rating in a research report on Friday, March 6th. Canaccord Genuity Group increased their price objective on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Finally, Citigroup lifted their target price on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, February 18th. Three research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.